Would you like to receive the latest vacancies in your e-mail box? Create a job alert based on your keyword(s) and preferences.
Principal Scientist, In silico Discovery (R5445)
Genmab is focused on the creation and development of innovative and differentiated antibody products, with the aim of improving the lives of cancer patients.
Within the Cell and Molecular Biology (CMS) department we have an open position for an In Silico Discovery scientist. You will be embedded within a team of Molecular Biologists and complement this team with state-of-the-art knowledge about in silico sequence-based predictions.
Within this team we focus on technology innovation specifically focused on the generation of new antibody discovery pipelines, generation of antibody libraries and development of sequence-based antibody characterization methods. The CMS department is embedded in the Antibody Discovery Technologies cluster highly collaborating with departments focusing on innovation with respect to high throughput screening, protein production, purification and characterization and automation.
You will complement the team with your experience with the development of antibody-based prediction pipelines, participating in building prediction models at the intersection of molecular biology and data science.
You will build and implement prediction models focused on the generation of antibody libraries and development of sequence-based antibody characterization methods (e.g. humanization, immunogenicity, affinity and epitope/paratope mapping).
Your knowledge will be applied to specific problems in the protein sequence space like library design optimization, establishing protein characteristics based on enrichment studies, generation of sequence-based prediction models, antibody optimization and de novo antibody design.
Genmab is a highly collaborative environment. You will work in close collaboration with other data scientists within the organization as well as participate with scientist responsible for new antibody formats, new antibody products and discovery technologies programs.
Besides hands-on activities, you are expected to initiate and participate in the formation of strategies and future plans and participation in external communities.
You are passionate about high volume sequence-based challenges and have a proven track record with the generation of sequence-based machine learning models. You are an Innovative and curious thinker, enthusiastic and passionate to drive new innovations. Furthermore, you have a practical and focused mindset and you are well organized.
You have 8 years' experience preferably in the antibody field, ideally in the Biotech industry
You are a strong communicator and able to bridge biology within silico approaches
You have a forward looking and strong strategic mindset
You have a proven track record in combining wet lab expertise with computational techniques, e.g. with the development of sequence-based prediction models.
You have excellent programming skills and expert knowledge of Python, SQL and R. Java knowledge and experience with Genedata is considered a big plus.
Genmab will offer the successful application a challenging position, where the right candidate will have the opportunity to work with highly specialised people across functions in an informal, multicultural environment, with an aim to make a difference in the lives of people with cancer.
At Genmab, we pride ourselves on our unique culture. We are committed to make a positive impact on the lives of cancer patients. We hypothesize and experiment to seek innovative solutions, no matter the employee’s role; we speak up, empower each other, and embrace change and growth; we respect and celebrate our differences while working as one team. Teamwork and respect are central pillars of Genmab’s culture and we therefore ensure an inclusive, open, and supportive professional work environment across our international locations. Genmab employees work with determination, challenge the status quo and cultivate a growth mindset in everything we do.
We are committed to fostering workplace diversity at all levels of the company and we believe it is essential for our continued success. No applicant shall be discriminated against or treated unfairly because of their race, color, religion, sex (including pregnancy, gender identity, and sexual orientation), national origin, age, disability or genetic information.
Please note that if you are applying for a position in the Netherlands; Genmab’s policy for all permanently budgeted hires in this location is initially to offer a fixed-term employment contract for a year, if the employee performs well and if the business conditions do not change, renewal for an indefinite term may be considered after the fixed-term employment contract.
Please be alerted that at the moment a recruitment scam involving Genmab is circulating. The scam involves recruiters on LinkedIn and elsewhere, pretending to be Genmab employees, headhunting candidates, asking for CVs and other personal information. The scam can include asking for payment for interviews or interview preparation. This communication is not coming from Genmab, we encourage people to stay alert and not to respond to these queries.
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab’s vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people’s lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.
Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.